A detailed history of Gsa Capital Partners LLP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 633 shares of REGN stock, worth $425,996. This represents 0.05% of its overall portfolio holdings.

Number of Shares
633
Holding current value
$425,996
% of portfolio
0.05%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$1024.09 - $1201.76 $648,248 - $760,714
633 New
633 $665,000
Q4 2023

Feb 16, 2024

BUY
$775.18 - $881.7 $355,807 - $404,700
459 New
459 $403,000
Q4 2022

Feb 13, 2023

SELL
$705.89 - $766.39 $367,768 - $399,289
-521 Reduced 59.2%
359 $259,000
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $200,889 - $253,512
350 Added 66.04%
880 $606,000
Q2 2022

Aug 09, 2022

BUY
$548.35 - $738.84 $290,625 - $391,585
530 New
530 $313,000
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $1.21 Million - $1.49 Million
-2,228 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $1.06 Million - $1.26 Million
1,850 Added 489.42%
2,228 $1.35 Million
Q2 2021

Aug 05, 2021

BUY
$472.8 - $558.54 $178,718 - $211,128
378 New
378 $211,000
Q2 2020

Aug 11, 2020

SELL
$493.32 - $643.92 $208,181 - $271,734
-422 Closed
0 $0
Q1 2020

May 12, 2020

SELL
$336.18 - $494.43 $194,312 - $285,780
-578 Reduced 57.8%
422 $206,000
Q4 2019

Feb 12, 2020

SELL
$274.13 - $376.51 $632,692 - $868,985
-2,308 Reduced 69.77%
1,000 $375,000
Q3 2019

Nov 12, 2019

BUY
$273.46 - $318.39 $455,310 - $530,119
1,665 Added 101.34%
3,308 $918,000
Q2 2019

Aug 06, 2019

SELL
$299.6 - $414.82 $833,487 - $1.15 Million
-2,782 Reduced 62.87%
1,643 $514,000
Q1 2019

May 15, 2019

BUY
$372.08 - $439.57 $641,838 - $758,258
1,725 Added 63.89%
4,425 $1.82 Million
Q4 2018

Feb 12, 2019

BUY
$335.82 - $403.04 $906,714 - $1.09 Million
2,700 New
2,700 $1.01 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $72.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.